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DObjectives: Durability of bioprosthetic valves in the pulmonary position is not well defined. We examined the
durability of bioprosthetic valves in the pulmonary position and risk factors associated with bioprosthetic
pulmonary valve failure.
Methods: Between 1993 and 2004, 181 patients underwent pulmonary valve replacement using bioprostheses.
Patientswho underwent valved conduit or homograft implantationwere excluded.Mean agewas 14.2 9.8 years
and median valve size was 23 mm (range, 19–27 mm). Types of bioprosthesis used were Hancock II (n ¼ 83),
Perimount (n ¼ 53), Freestyle (n ¼ 23), Carpentier–Edwards porcine valve (n ¼ 18), and others (n ¼ 4).
Results: There were 3 early and 7 late deaths. Follow-up completeness was 88.6% and mean follow-up duration
was 7.3  2.9 years. Forty-three patients underwent redo pulmonary valve replacement. Overall freedom from
redo pulmonary valve replacement at 5 and 10 yearswas 93.9% 1.9% and 51.7% 8.6%, respectively. Overall
freedom from both valve failure and valve dysfunction at 5 and 10 years was 92.2% 2.1% and 20.2% 6.7%,
respectively. In multivariable analysis, younger age at operation, diagnosis of pulmonary atresia with ventricular
septal defect, and use of stentless valve were identified as risk factors for redo pulmonary valve replacement.
Conclusions: Durability of bioprosthetic valves in the pulmonary position was suboptimal. Valve function was
maintained stable until 5 years after operation. By 10 years, however, about 80% will require reoperation or
manifest valve dysfunction. In our experience, the stentless valve was less durable than stented valves. (J Thorac
Cardiovasc Surg 2011;142:351-8)Earn CME credits at
http://cme.ctsnetjournals.org
Pulmonary valve replacement (PVR) is frequently per-
formed during repair of various congenital heart diseases.
Chronic pulmonary regurgitation after repair of tetralogy
of Fallot is a typical situation that necessitates PVR. There
are several surgical options for PVR, including bioprosthe-
ses, homografts, mechanical valves, and hand-sewn polyte-
trafluoroethylene valves.1-5 Among these, bioprosthetic
valves are probably the most widely used, because they are
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bioprostheses will eventually fail and require replacement
mainly owing to structural valve deterioration, more
specifically, leaflet calcification. Although modern design
technique and anticalcification treatments applied to
currently available bioprosthetic valves have greatly
improved the durability of bioprostheses implanted into
adult patients,6,7 dystrophic calcification leading to early
bioprosthetic valve failure is still a great problem in
children and young adults. A dominant risk factor
predictive of early bioprosthetic pulmonary valve failure is
younger age at the time of initial PVR, as reported in
previous studies.1,8 However, long-term actual durability of
bioprosthetic pulmonary valves implanted into children
and young adults is not well defined owing to the small num-
ber of patients or relatively short duration of follow-up in pre-
vious studies.1-3,9-13 Furthermore, many studies2,10,11,14 are
limited to a single valve type, and there are few reports3,13
dealing with durability of different types of bioprostheses.
Since 1993, we have performed over 280 initial PVR in
patients with various congenital heart defects using differ-
ent types of bioprostheses. To better elucidate the fate of bi-
oprosthetic pulmonary valves, we examined the long-term
durability of these valves and risk factors associated with
bioprosthetic pulmonary valve failure.rdiovascular Surgery c Volume 142, Number 2 351
Abbreviations and Acronyms
PA ¼ pulmonary atresia
PVR ¼ pulmonary valve replacement
VSD ¼ ventricular septal defect




By searching the database of our institution, we identified 281 patients
who had undergone initial PVR using bioprosthetic valves between 1993
and 2009. From among these patients, we selected 181 patients who had
undergone PVR between 1993 and 2004 to examine the long-term results
of bioprosthetic PVR. Excluded from this study were patients who had
undergone valved conduit or homograft implantation. The medical records
of these patients were reviewed. The institutional review board at our
institution has approved this retrospective study and waived the need for
individual patient consent.
The mean age at the time of PVRwas 14.2 9.8 years (Figure 1, A) and
112 patients (61.9%) were male. Fundamental diagnoses were tetralogy of
Fallot (n ¼ 97), pulmonary atresia (PA) with ventricular septal defect
(VSD) (n ¼ 39), double-outlet right ventricle (n ¼ 10), transposition of
the great arteries (n ¼ 9), pulmonary stenosis (n ¼ 8), congenitally cor-
rected transposition of the great arteries (n ¼ 6), absent pulmonary valve
syndrome (n¼ 6), and others (n¼ 6). Indications for PVRwere pulmonary
regurgitation (n¼ 112), pulmonary stenosis (n¼ 43), combined pulmonary
stenosis and regurgitation (n ¼ 14), and as a part of corrective surgery
(n ¼ 12). The mean number of operations before PVR was 1.5  0.8 and
the mean interval between initial right ventricular outflow tract reconstruc-
tion and PVR was 9.1  5.0 years.
Choice of bioprosthetic valves was at the discretion of the surgeon.
Valve types used were Hancock II (Medtronic, Inc, Minneapolis, Minn;
n ¼ 83), Carpentier–Edwards Perimount (Edwards Lifesciences, Irvine,
Calif; n ¼ 53), Freestyle (Medtronic; n ¼ 23), Carpentier–Edwards por-
cine valves (Edwards Lifesciences; n ¼ 18), and others (n ¼ 4). For the
entire cohort, the median valve size was 23 mm (range, 19–27 mm) and
the distribution of valve sizes is shown in Figure 1, B. So that valve sizes
could be compared across a broad range of age groups, Z-scores were cal-
culated according to the formulas developed by Zilberman, Khoury, and
Kimball.15 The median Z-score was 1.3 (range,0.5 to 3.6). Concurrent
procedures were performed in 141 (77.9%) patients and are summarized
in Table 1. The mean cardiopulmonary bypass time was 184  77 minutes
and the mean aortic crossclamp time (n ¼ 77) was 95  57 minutes. Post-
operative pressure data were available for 96 (53%) patients, and the
mean systolic pressure ratio between the right and left ventricles was
0.39  0.13.FIGURE 1. A, Distribution of patient ages at the time of pulmonary v
352 The Journal of Thoracic and Cardiovascular SurgPatient follow-up data were obtained through review of medical records
and direct telephone contact between March 8, 2010, and March 16, 2010.
Follow-up was considered complete if the patient’s status was determined
after July 2008. The mean duration of follow-up was 7.3  2.9 years
(range, 0.1–16.0 years [1148 patient-years]), and 84.8% of hospital survi-
vors had complete follow-up. Follow-up completeness measured by calcu-
lating the index devised by Clark and associates,16 as previously
described, was 88.6%. Prosthetic valve failure was defined as the need
for redo PVR or interventional catheter procedure. Prosthetic valve dys-
function was defined as a peak pressure gradient equal to or greater than
40 mm Hg or at least a moderate amount of pulmonary regurgitation on
the latest echocardiography.
Data collection and statistical analyses adhered to the guidelines for
reporting mortality and morbidity after cardiac valve interventions.17
Categorical variables were expressed as frequencies and percentages.
Continuous variables were expressed as means  standard deviations or
medians with ranges as appropriate. Comparison between groups was per-
formed using 1-way analysis of variance with post hoc test. Survival and
time-to-event analyses were performed using the Kaplan–Meier actuarial
method. Stratified Kaplan–Meier curve comparisons were performed using
the log rank test. The Cox proportional hazardmodel was used to determine
both univariable and multivariable relationships between explanatory
variables and time-to-event.RESULTS
Early and Late Mortality
There were 3 early deaths (30-day hospital mortality,
1.7%). A 38-year-old man with underlying liver cirrhosis,
who had undergone repair of tetralogy of Fallot at the age
of 33 years, died of massive tracheal bleeding 11 days after
the operation. An 11-year-old boy with preoperative ven-
tricular dysfunction, who had undergone a conventional
Rastelli procedure for congenitally corrected transposition
of the great arteries, VSD, and pulmonary stenosis at the
age of 5 years, died of ventricular dysfunction on the day
of the operation. A 10-year-old boy, who had undergone re-
pair of tetralogy of Fallot at the age of 3 years, died of ische-
mic brain damage 8 days after the operation. There were 7
late deaths. The causes of late death were accident in 2 pa-
tients, ventricular dysfunction in 1 patient, multiorgan fail-
ure in 1 patient, endocarditis in 1 patient, and unknown in 2
patients. Overall actuarial survival (including early deaths)
at 5 and 10 years was 96.1%  1.5% and 93.7%  2.0%,
respectively.alve replacement. B, Distribution of bioprosthetic valve sizes used.
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TABLE 1. Concurrent procedures
Procedure No. Percent
PA angioplasty 88 48.6
TAP/TVP 41 22.7
VSD closure 30 16.6
Arrhythmia surgery 10 5.5





PA, Pulmonary artery; TAP, tricuspid annuloplasty; TVP, tricuspid valvuloplasty;
VSD, ventricular septal defect; ASD, atrial septal defect; AVP, aortic valvuloplasty;
LVOT, left ventricular outflow tract.
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Prosthetic Valve Dysfunction
Among 178 hospital survivors, 43 patients required reop-
eration for a failed pulmonary valve prosthesis. Indications
for reoperation were pulmonary stenosis (n¼ 30), endocar-
ditis (n ¼ 7), and combined pulmonary stenosis and regur-
gitation (n ¼ 6). The linearized rate of endocarditis was
0.6% per year. The majority of reoperations were associ-
ated with some degree of pulmonary stenosis and the clini-
cal thresholds for consideration of reoperation have
somewhat varied between individual patients over the study
period. For patients who underwent reoperation owing to
pulmonary stenosis, the median peak pressure gradient as-
sessed by echocardiography or cardiac catheterization was
63 mm Hg (range, 31–114 mm Hg). The median time inter-
val between initial PVR and redo PVRwas 6.4 years (range,
0.5–13.6 years). Overall freedom from redo PVR at 5 and
10 years was 93.9%  1.9% and 51.7%  8.6%, respec-
tively (Figure 2, A).
Ten patients underwent interventional balloon valvulo-
plasty for prosthetic valve stenosis (median peak pressure
gradient of 55 mm Hg [range, 42–80 mm Hg]), and 8 of
these eventually required reoperation. Excluding the pa-
tients who underwent redo PVR or interventional balloonFIGURE 2. A, Overall freedom from reoperation. B, Overall freedom from bo
resent patients remaining at risk.
The Journal of Thoracic and Cavalvuloplasty, 22 patients showed prosthetic valve dysfunc-
tion on the latest echocardiogram. Overall freedom from
both prosthetic valve failure and dysfunction at 5 and 10
years was 92.2% 2.1% and 20.2% 6.7%, respectively
(Figure 2, B).Valve Type–Stratified Analysis
To compare the durabilities of different types of biopros-
theses, we categorized them into 3 groups: stented porcine
valve (Hancock II, Carpentier–Edwards porcine, and
others; n¼ 105), stented bovine pericardial valve (Carpent-
ier–Edwards Perimount, n ¼ 53), and stentless porcine
valve (Freestyle, n ¼ 23). Stentless porcine valve was asso-
ciated with a lower mean age and a smaller mean valve size
(Table 2). Stented bovine pericardial valve was associated
with a smaller mean valve Z-score and a shorter mean
follow-up duration (Table 2). Freedom from redo PVR at
10 years was 48.5%  10.9% for stented porcine valve,
84.6%  7.8% for stented bovine pericardial valve, and
31.2%  10.4% for stentless porcine valve (Figure 3, A).
Freedom from redo PVR for stentless porcine valvewas sig-
nificantly lower than those for stented porcine (P<.001)
and stented bovine pericardial valve (P<.001). The differ-
ence between stented porcine and stented bovine pericardial
valve could be due to chance (P ¼ .293). Freedoms from
both prosthetic valve failure and dysfunction are plotted
in Figure 3, B. Freedom from valve failure and dysfunction
for stentless porcine valve was significantly lower than
those for stented porcine (P<.001) and stented bovine peri-
cardial valves (P ¼ .015). There was no significant differ-
ence between stented porcine and stented bovine
pericardial valvea (P ¼ .311).Diagnosis-Stratified Analysis
We categorized underlying diagnoses into 3 groups; te-
tralogy of Fallot (n¼ 97), PAwith VSD (n¼ 39), and others
(n ¼ 45). Diagnosis of PA with VSD was associated with
a lower mean age, a smaller mean valve size, and a largerth prosthetic valve failure and dysfunction. Numbers above the x-axis rep-
rdiovascular Surgery c Volume 142, Number 2 353









Mean age (y) 14.8  10.6 15.5  8.3 8.3  4.9 .007
Mean valve size (mm) 23.2  2.5 23.3  2.6 21.1  2.4 .001
Mean valve Z-score 1.5  0.8 1.1  0.8 1.6  0.7 .027
Mean FU (y) 7.8  3.1 6.1  2.2 7.6  2.7 .003
FU, Follow-up.
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ference in follow-up duration among the 3 groups (Table 3).
Freedoms from redo PVR according to the underlying diag-
nosis are plotted in Figure 4, A. Freedom from redo PVR for
tetralogy of Fallot was significantly higher than those for PA
with VSD (P<.001) and other diagnoses (P¼ .008). There
was no significant difference between PA with VSD and
other diagnoses (P ¼ .235). Freedoms from both prosthetic
valve failure and dysfunction are plotted in Figure 4, B.
Freedom from valve failure and dysfunction for tetralogy
of Fallot was significantly higher than those for PA with
VSD (P< .001) and other diagnoses (P ¼ .007). There
was no significant difference between PA with VSD and
other diagnoses (P ¼ .173).
Age-Stratified Analysis
Freedom from redo PVR at 10 years was 17.8% 7.1%
for patients younger than 10 years and 90.6%  4.1% for
patients older than 10 years (P<.001; Figure 5, A). Free-
dom from both prosthetic valve failure and dysfunction at
10 years was 6.2%  4.2% for patients younger than 10
years and 12.6%  10.8% for patients older than 10 years
(P<.001; Figure 5, B).
Risk Factors for Redo PVR
In univariable analysis, younger age at operation, under-
lying diagnosis of PA with VSD, use of stentless porcineFIGURE 3. Valve type-stratified Kaplan–Meier curves. A, Freedom from reo
Numbers below the graph represent patients remaining at risk. SP, Stented porc
354 The Journal of Thoracic and Cardiovascular Surgvalve, and larger valve Z-score were identified as risk fac-
tors associated with decreased time to redo PVR (Table
4). In multivariable analysis, younger age, diagnosis of
PAwith VSD, and use of stentless porcine valve were iden-
tified as independent risk factors for redo PVR (Table 4).DISCUSSION
Surgical repair of obstructive lesions of the right ventric-
ular outflow tract in children usually leaves the native pul-
monary valve incompetent or requires placement of
a conduit between the right ventricle and pulmonary artery.
As these patients grow, many of them will require PVR ow-
ing to chronic pulmonary regurgitation or a failed conduit.
There are several surgical options for PVR, including bio-
prostheses, homografts, mechanical valves, and hand-
sewn polytetrafluoroethylene valves. The homograft has
a drawback of limited availability, and there are limited
experiences about implanting mechanical valves in the
pulmonary position.4,18 For these reasons, bioprosthetic
valves are widely used and they have been our first choice
for PVR in patients who can accommodate an adult-sized
bioprosthesis.
Bioprosthetic PVR can be performed with low operative
mortality as evidenced by our result (30-day hospital mor-
tality of 1.7%). However, almost all of these bioprostheses
will eventually fail and require replacement owing to struc-
tural valve deterioration. Structural valve deterioration in
the form of leaflet calcification is accelerated in children
and young adults, resulting in early prosthetic valve failure.
Compatible with previous studies,1,8 our study also
demonstrated that younger age was a significant risk
factor for early prosthetic pulmonary valve failure (hazard
ratio: 0.85 per year, P ¼ .001). Currently, the exact cause
and mechanism of an accelerated bioprosthetic valve
failure in children are not completely understood.
Traditionally, active calcium metabolism of rapidlyperation. B, Freedom from both prosthetic valve failure and dysfunction.
ine valve; SB, stented bovine pericardial valve; SL, stentless valve.
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TABLE 3. Comparison among 3 diagnostic groups
TOF PAwith VSD Others P value
Mean age (y) 16.2  9.7 10.2  5.6 13.5  11.6 .005
Mean valve size (mm) 23.7  2.5 22.2  2.7 22.2  2.4 .001
Mean valve Z-score 1.3  0.7 1.7  0.9 1.3  0.8 .027
Mean FU (y) 6.8  3.1 7.5  3.0 7.6  2.8 .281
TOF, Tetralogy of Fallot; PA, pulmonary atresia; VSD, ventricular septal defect; FU,
follow-up.
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recently, however, some evidences suggest that the greater
immune system competence of children and young adults
may contribute to an accelerated bioprosthetic valve
failure.19-21
The primary objective of our study was to better define
the durability of bioprostheses in the pulmonary position
through long-term follow-up. Although many previous
studies have dealt with this issue, most of them had limita-
tions of relatively small patient numbers or short duration of
follow-up (Table 5). Caldarone and coworkers8 reported
a large series of PVR using 455 bioprostheses. However,
their study also included 490 valved conduits and they did
not make a separate analysis on the durability of bioprosthe-
ses. In our experience, bioprosthetic valve function was
maintained stable until 5 years after the operation, as evi-
denced by overall freedom from redo PVR of 94% and free-
dom from valve failure and dysfunction of 92% at 5 years.
This result is fairly compatible with those of previous stud-
ies3,22-24 reporting 5-year freedom from redo PVR (92%–
100%, Table 5). At 10 years after operation, however, the
result was disappointing with freedom from redo PVR of
52% and freedom from valve failure and dysfunction of
only 20%. Although previous studies1,25 reporting 10-
year freedom from redo PVR gave somewhat higher
values (70%–86%, Table 5) compared with ours, their
mean ages were higher and this might be able to explainFIGURE 4. Diagnosis-stratified Kaplan–Meier curves. A, Freedom from reo
Numbers below the graph represent patients remaining at risk. TOF, Tetralogy
The Journal of Thoracic and Cathe differences. Certainly, all of these results, including
ours, are suboptimal when considering the results from
old-aged adult patients.6,7
Valve type–stratified analysis revealed an interesting
finding, that is, inferior durability of stentless porcine valve
(Freestyle) compared with those of stented porcine or
bovine valves. The Freestyle valve was considered as an
attractive alternative for right ventricular outflow tract re-
construction in children owing to its presumed favorable he-
modynamic characteristics and anticalcification treatment
using amino oleic acid.10,14 Previous studies dealing with
PVR using different kinds of stentless porcine valves
consistently reported excellent early results in terms of
freedom from redo PVR (Table 5). However, our long-
term follow-up result (mean follow-up duration of 7.6
years) was disappointing, with freedom from redo PVR of
only 31% at 10 years (Figure 3, A), although our patients
were younger and had smaller valves implanted (Table 2).
Kanter and coworkers10 reported excellent early results
with the Freestyle valve for right ventricular outflow tract
reconstruction in children with only 1 reoperation out of
56 patients during a mean follow-up of 2.5 years. However,
they observed a mean peak systolic gradient of 19.7 mm Hg
across the valves and questioned the significance of this
finding in the long term. Other studies dealing with PVR us-
ing stentless valves also reported similar echocardiographic
findings (mean peak systolic transvalvular gradients of 25–
26 mm Hg) and also questioned the significance of their
findings in the long term.14,23,24 Although it was
anticipated hopefully that the anticalcification treatment
applied to the Freestyle valve could delay the onset of
calcification and, as such, would improve the durability of
this valve in children, this was not the case, at least in our
experience. Most of the explanted Freestyle valves
showed variable degrees of leaflet calcification. Of note,
in 3 patients, we found at the time of reoperation that theperation. B, Freedom from both prosthetic valve failure and dysfunction.
of Fallot; PA, pulmonary atresia; VSD, ventricular septal defect.
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FIGURE 5. Age-stratified Kaplan–Meier curves. A, Freedom from reoperation. B, Freedom from both prosthetic valve failure and dysfunction. Numbers
below the graph represent patients remaining at risk.
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these patients had previously undergone implantation of
a conduit for right ventricular outflow tract reconstruction
before PVR. We speculate that nonorthotopic
implantations of Freestyle valves in these patients might
have caused compression by the sternum, further reducing
the durability of these valves. Whether the inferior
durability of Freestyle valves is simply a reflection of our
patients’ characteristics or a true long-term fate of this valve
remains elusive, although our multivariable analysis identi-
fied this valve type as an independent risk factor for early
redo PVR. Long-term follow-up studies from other groups
with different patient populations will be helpful to clarify
this point. Currently, we no longer use the Freestyle valve
for right ventricular outflow tract reconstruction. Instead,
we use hand-sewn polytetrafluoroethylene (0.1-mm thick-
ness) bicuspid valve as described by Quintessenza andTABLE 4. Risk factors associated with redo PVR
Variable
Univariable analysis
HR 95% CI P va
Sex
Male Reference category
Female 1.27 0.69–2.33 .4
Age (y) 0.86 0.81–0.91 <.0
Diagnosis
TOF Reference category
PA/VSD 4.31 1.95–9.54 <.0
Others 2.78 1.25–6.20 .0
Valve type
Stented P Reference category
Stented B 0.53 0.18–1.53 0.2
Stentless 3.73 1.91–7.29 <0.0
Z-score 1.81 1.29–2.54 0.0
PVR, Pulmonary valve replacement; HR, hazard ratio; CI, confidence interval; TOF, tet
B, bovine.
356 The Journal of Thoracic and Cardiovascular Surgcoworkers5 or stented bovine pericardial valve depending
on the surgeon’s preference.
Diagnosis-stratified analysis revealed superior durability
of bioprosthetic valves when implanted into patients with
tetralogy of Fallot (Figure 4). In most of the patients with
a diagnosis of tetralogy of Fallot, the indication for PVR
was chronic pulmonary regurgitation, and it was almost al-
ways possible to implant a bioprosthesis in the orthotopic
position. On the contrary, a substantial portion of patients
with other types of diagnosis underwent PVR owing to
failure of a pre-existing conduit used for right ventricular
outflow tract reconstruction. Accordingly, many of these
patients had their valves implanted in a nonorthotopic posi-
tion, and this might have contributed to the inferior durabil-
ity of the bioprostheses implanted into these patients. It is
our speculation that turbulent blood flow across a nonortho-
topically implanted bioprosthesis can lead to early valveMultivariable analysis
lue HR 95% CI P value
49
01 0.85 0.78–0.93 .001
Reference category
01 3.24 1.44–7.26 .004
12 1.58 0.65–3.83 .313
Reference category
38 0.79 0.26–2.36 .671
01 3.10 1.39–6.90 .006
01 0.81 0.50–1.33 .411
ralogy of Fallot; PA, pulmonary atresia; VSD, ventricular septal defect; P, porcine;
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TABLE 5. Summary of reported results for bioprosthetic PVR
Author Patients No. Age (y) Valve type Valve size (mm) FU (y) Freedom from redo PVR
Fiore et al3 49 23.0 Porcine 25 1.7 78% at 5 y
Kanter et al9 38 11.4 Porcine 26 4.9 100% at 8 y
Allen et al22 48 11.0 Bovine 26 3.6 100% at 5 y
Morales et al11 26 20.3 Bovine 23 1.6 100% at 2.5 y
Fiore et al3 18 22.0 Bovine 24 3.5 92% at 5 y
Hawkins et al23 150 15.8 Stentless 27 — 99% at 5 y
Kanter et al10 56 11.8 Stentless 24 2.5 1 reoperation
Hartz et al14 47 14.2 Stentless 25 3.5 1 reoperation
Black et al24 21 24.5 Stentless 27 3.1 100% at 5 y
Yemets et al25 79 19.6 Mixed — 5.8 86% at 10 y
Discigil et al1 33 22.0 Mixed 25 7.8 70% at 10 y
Age, valve size, and follow-up duration are expressed as a mean value. PVR, Pulmonary valve replacement; FU, follow-up.
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In multivariable analysis, diagnosis of PA with VSD was
identified as an independent risk factor for redo PVR.
When stratified by age, it appears that bioprostheses im-
planted into patients older than 10 years have quite excel-
lent durability in terms of reoperation (Figure 5, A).
However, if we consider both valve failure and dysfunction
together, it was very interesting to find that the two curves
for each age group had very similar pattern except a slightly
longer initial stable period observed in older children
(Figure 5, B). Certainly, bioprostheses implanted into older
children also have suboptimal durability and will require
reoperations in the near future.
CONCLUSIONS
Overall durability of bioprosthetic valves in the pulmo-
nary position was suboptimal. Valve function can be ex-
pected to remain stable until 5 years after the operation.
By 10 years, however, about 80% will require reoperation
or manifest valve dysfunction. Younger age and diagnosis
of PAwith VSD were identified as independent risk factors
for redo PVR. In our experience, the stentless porcine valve
was less durable than stented valves.
Limitations of the Study
This study is limited by its retrospective design and inclu-
sion of patients managed over a 16-year period. Choice of
bioprosthetic valves was at the discretion of the surgeon.
Also, it is important to acknowledge that the follow-up
was incomplete (89%).
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